Tony Berberabe, MPH

Radium-223 prior to docetaxel improved quality of life and tolerability in patients with metastatic castration-resistant prostate cancer according to data from the RAPSON trial.

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.

In patients with NSCLC refractory to anti-PD(L)1 therapy, CAN-2409 (adenovirus) plus valacyclovir co-administered with ICI therapy showed acceptable tolerability and potential for immune modulation

Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Adjuvant chemotherapy did not improve circulating tumor DNA clearance in patients with stage II colon cancer with baseline circulating tumor DNA.

The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.

Treatment with subcutaneous epcoritamab-bysp elicited rapid and durable responses, including an encouraging complete response rate, and manageable safety in high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

Forimtamig monotherapy generated high overall response rates and durable responses in all subgroups of patients with relapsed/refractory multiple myeloma enrolled in a phase 1a dose-escalation trial.

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.

Ibrutinib did not prolong survival vs placebo and is linked with increased susceptibility to bleeding in patients with asymptomatic early-stage chronic lymphocytic leukemia, suggesting that a watch-and-wait approach should continue as the standard for this population.

The addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple myeloma who were able to meet their stem cell collection goals on first attempt.

Treatment with doxorubicin plus zalifrelimab and balstilimab produced a favorable 6-month progression-free survival rate in patients with difficult-to-treat soft tissue sarcoma subtypes unlikely to respond to doxorubicin or immune checkpoint inhibitor monotherapy.

The CAR T-cell therapy PHE885 produced responses and high minimal residual disease negativity rates with no new safety signals in patients with relapsed/refractory multiple myeloma.

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.

Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.

Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.

ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.

REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Pembrolizumab plus chemotherapy with or without bevacizumab prolonged progression-free survival and overall survival in key subgroups of patients with persistent, recurrent, or metastatic cervical cancer, displaying benefits similar to those seen in the broader patient population.

Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.

The combination of lenvatinib and pembrolizumab demonstrated clinically meaningful improvements in progression-free survival on next line of therapy among all-comer patients with advanced endometrial cancer and those with DNA mismatch repair proficient disease, according to an exploratory analysis of the phase 3 KEYNOTE-775 trial.

The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.

Infigratinib yielded notable activity and tolerability in patients with localized upper tract urothelial carcinoma harboring FGFR1/2/3 mutations.

Patients with low-grade non-muscle invasive bladder cancer who received the chemoablative reverse thermal gel UGN-102 were found to have maintained health-related quality-of-life outcomes.